ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - riltozinameran 0.05 mg/ml equivalent to 15µg/0.3ml dose;  ;  ;  ;  ; tozinameran 0.05 mg/ml equivalent to 15µg/0.3ml dose;  ;  ;  ;   - suspension for injection - 0.1 mg/ml - active: riltozinameran 0.05 mg/ml equivalent to 15µg/0.3ml dose         tozinameran 0.05 mg/ml equivalent to 15µg/0.3ml dose         excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine alc-0159 alc-0315 cholesterol sucrose trometamol trometamol hydrochloride water for injection - comirnaty has provisional consent for the indication below: active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. the use of this vaccine should be in accordance with official recommendations.

イスラエル - 英語 - Ministry of Health

propharm ltd - baclofen - solution for injection - baclofen 10 mg / 5 ml - baclofen - baclofene bioindustria l.i.m. 10mg/5ml is indicated in patients with severe chronic spasticity resulting from trauma, multiple sclerosis or other spinal cord disorders, who are unresponsive to oral baclofen or other orally administered antispastic agents and/or those patients who experience unacceptable side effects at effective oral doses.baclofene bioindustria l.i.m. 10mg/5ml is effective in adult patients with severe chronic spasticity of cerebral origin, resulting e.g. from cerebral palsy, brain trauma or cerebrovascular accident; however, clinical experience is limited.pediatric population:baclofene bioindustria l.i.m. 10mg/5ml is indicated in patients aged 4 to <18 years with severe chronic spasticity of cerebral origin or of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

マレーシア - 英語 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

biocon sdn bhd - insulin aspart -

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

publix super markets inc - oxymetazoline hydrochloride (unii: k89mj0s5vy) (oxymetazoline - unii:8vln5b44zy) - nasal decongestant

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

publix super markets inc - magnesium hydroxide (unii: nbz3qy004s) (magnesium cation - unii:t6v3lhy838, hydroxide ion - unii:9159uv381p) - saline laxative

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

mighty munch australia pty ltd - chondroitin as chondroitin sulfate (avian origin); glucosamine as glucosamine sulphate (shellfish origin); methylsulphonylmethane (msm) - oral powder, pre-mix - chondroitin as chondroitin sulfate (avian origin) active 176.0 mg/g; glucosamine as glucosamine sulphate (shellfish origin) active 501.5 mg/g; methylsulphonylmethane (msm) other 190.0 mg/g - musculoskeletal system

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - recombinant omega interferon of feline origin - unknown - recombinant omega interferon of feline origin vaccine active 0.0 - active constituent

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

miguhara - glycerin (unii: pdc6a3c0ox) (glycerin - unii:pdc6a3c0ox) - purpose: skin protectant

マレーシア - 英語 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

the origin foods sdn bhd - ginkgo biloba -

サウジアラビア - 英語 - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

stallergens, france - allergen extract "animal origin initial" - solution - 100 mg/ml